Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07801027 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)

StatusNot Yet Recruiting
PhasePhase 4
Started2026-11-06
View on ClinicalTrials.gov ↗
The goal of this study is to assess the safety of pembrolizumab with chemotherapy or chemoradiotherapy in participants in India for: * Advanced gastric or gastroesophageal junction \[GEJ\] cancer that is (human epidermal growth factor receptor 2 \[HER2\]-negative and has a programmed death-ligand 1 \[PD-L1\] combined positive score \[CPS\] ≥1 * Advanced and/or unresectable biliary tract cancer \[BTC\], and * High-risk, locally advanced cervical cancer
Trial Details
NCT Number NCT07801027
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Neoplasm Malignant, Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Carcinoma, Uterine Cervical Neoplasms
Enrollment 150 participants
Start Date 2026-11-06
Primary Completion 2030-01-31 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-03